Archives
ASCO: Encorafenib + Cetuximab + Chemo Lengthens Survival in Metastatic CRC
Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations
ASCO: AI Training Improves Accuracy of HER2 Immunohistochemistry Scoring
For HER2 clinical categories, accuracy improved from 66.7 percent without AI to 88.5 percent with AI
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes
ASCO: Alcohol-Associated Cancer Mortality Increased From 1990 to 2021
Mortality rates significantly higher in those aged 55 years and older and men in the United States
ASCO: Maintenance Lurbinectedin + Atezolizumab Enhances Survival in Lung Cancer
Findings seen for patients with extensive-stage small cell lung cancer, following standard induction therapy
One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years
Five-fraction schedule over one week as safe and effective as standard three-week schedule in adjuvant breast radiotherapy
Severe Exacerbations Down With As-Needed Albuterol-Budesonide for Mild Asthma
Severe exacerbation occurred in fewer patients receiving albuterol-budesonide versus those receiving albuterol only
Intravenous Tenecteplase Beneficial Before Endovascular Thrombectomy
Higher functional independence seen at 90 days for patients with acute ischemic stroke due to large vessel occlusion who present within 4.5 hours
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
Strong outcomes seen in terms of weight loss, with lower doses of semaglutide used
Trend Toward Survival Benefit Seen for REM-Inhibition in ALS
REM inhibition via receipt of antidepressant medications associated with trend toward survival benefit












